A systematic review with meta-analysis of the relation of aflatoxin B1 to growth impairment in infants/children.


Journal

BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 20 04 2023
accepted: 25 08 2023
medline: 7 12 2023
pubmed: 6 12 2023
entrez: 5 12 2023
Statut: epublish

Résumé

Aflatoxins are regarded as the most potent genotoxic and carcinogenic type of mycotoxins. This meta-analysis was performed to investigate a the relation of aflatoxin B1 (AFB1) to growth measurements of infants/children, including wasting, underweight, stunting, as well as weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ) z-scores. Electronic databases of PubMed, Web of Science, and Scopus were searched to identify related publications. Effect sizes for associations were pooled using the random effects analysis. Subgroup analysis by study design, method used to assess AFB1, and adjustment for covariateswas performed to detect possible sources of heterogeneity. Pooled analysis of available data showed that AFB1 exposure was negatively associated growth z-scores, including WHZ (β = -0.02, 95%CI = -0.07 to 0.03), with WAZ (β = -0.18, 95%CI = -0.33 to -0.02), and HAZ (β = -0.17, 95%CI = -0.30 to -0.03) in infants/children. There was a remarkable heterogeneity among studies on WAZ and HAZ (P ≤ 0.001). In prospective cohort studies, AFB1 exposure was found to be significantly associated with the elevated risk of underweight (OR = 1.20, 95%CI = 1.03 to 1.40) and stunting (OR = 1.21, 95%CI = 1.11 to 1.33). This meta-analysis highlighted the importance of AFB1 exposure as a potential risk factor for growth impairment in infants/children.

Sections du résumé

BACKGROUND BACKGROUND
Aflatoxins are regarded as the most potent genotoxic and carcinogenic type of mycotoxins. This meta-analysis was performed to investigate a the relation of aflatoxin B1 (AFB1) to growth measurements of infants/children, including wasting, underweight, stunting, as well as weight-for-age (WAZ), height-for-age (HAZ), and weight-for-height (WHZ) z-scores.
METHODS METHODS
Electronic databases of PubMed, Web of Science, and Scopus were searched to identify related publications. Effect sizes for associations were pooled using the random effects analysis. Subgroup analysis by study design, method used to assess AFB1, and adjustment for covariateswas performed to detect possible sources of heterogeneity.
RESULTS RESULTS
Pooled analysis of available data showed that AFB1 exposure was negatively associated growth z-scores, including WHZ (β = -0.02, 95%CI = -0.07 to 0.03), with WAZ (β = -0.18, 95%CI = -0.33 to -0.02), and HAZ (β = -0.17, 95%CI = -0.30 to -0.03) in infants/children. There was a remarkable heterogeneity among studies on WAZ and HAZ (P ≤ 0.001). In prospective cohort studies, AFB1 exposure was found to be significantly associated with the elevated risk of underweight (OR = 1.20, 95%CI = 1.03 to 1.40) and stunting (OR = 1.21, 95%CI = 1.11 to 1.33).
CONCLUSIONS CONCLUSIONS
This meta-analysis highlighted the importance of AFB1 exposure as a potential risk factor for growth impairment in infants/children.

Identifiants

pubmed: 38053136
doi: 10.1186/s12887-023-04275-9
pii: 10.1186/s12887-023-04275-9
pmc: PMC10696779
doi:

Substances chimiques

Aflatoxin B1 9N2N2Y55MH
Aflatoxins 0

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

614

Informations de copyright

© 2023. The Author(s).

Références

Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Clin Nutr. 2020 Jul;39(7):2035-2044
pubmed: 31669002
Indian J Pediatr. 2012 Jan;79(1):56-61
pubmed: 21643863
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Environ Health Perspect. 2003 Feb;111(2):217-20
pubmed: 12573908
Sci Rep. 2021 Jan 15;11(1):1619
pubmed: 33452336
Public Health Nutr. 2021 Aug;24(11):3361-3370
pubmed: 32618233
Campbell Syst Rev. 2022 Mar 27;18(2):e1230
pubmed: 36911350
BMJ Glob Health. 2018 Dec 01;3(6):e000983
pubmed: 30588341
World Mycotoxin J. 2018;11(3):411-419
pubmed: 33552312
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Food Addit Contam. 2002 Nov;19(11):1073-80
pubmed: 12456279
Environ Health Perspect. 2006 Dec;114(12):1898-903
pubmed: 17185282
Environ Health Perspect. 2015 Feb;123(2):173-8
pubmed: 25325363
Int J Food Sci Nutr. 2020 Aug;71(5):593-603
pubmed: 31718342
PLoS One. 2017 Feb 17;12(2):e0172124
pubmed: 28212415
J Hum Hypertens. 2019 Jul;33(7):499-507
pubmed: 30846828
Public Health Nutr. 2021 Aug;24(12):3662-3673
pubmed: 33517942
World J Gastroenterol. 2013 Mar 14;19(10):1508-12
pubmed: 23539499
Crit Rev Food Sci Nutr. 2020;60(16):2773-2789
pubmed: 31478403
Int J Environ Health Res. 2018 Jun;28(3):280-292
pubmed: 29706087
Environ Health Perspect. 2004 Sep;112(13):1334-8
pubmed: 15345349
Matern Child Nutr. 2022 Apr;18(2):e13315
pubmed: 35020261
Matern Child Nutr. 2018 Oct;14(4):e12619
pubmed: 29781250
Compr Rev Food Sci Food Saf. 2021 May;20(3):2332-2381
pubmed: 33977678
Public Health. 2019 Sep;174:31-41
pubmed: 31306887
Am J Clin Nutr. 2021 Apr 6;113(4):874-883
pubmed: 33677532
Oncol Rep. 2017 Mar;37(3):1321-1336
pubmed: 28184933
Ann Nutr Metab. 2014;64 Suppl 2:42-52
pubmed: 25341872
BMC Public Health. 2018 Nov 09;18(1):1247
pubmed: 30413157
Food Chem Toxicol. 2018 Jan;111:356-362
pubmed: 29175577
Environ Int. 2018 Jun;115:29-37
pubmed: 29544138
Arch Endocrinol Metab. 2019 Jul 29;63(4):427-437
pubmed: 31365625
Adv Nutr. 2012 Jul 01;3(4):526-31
pubmed: 22797988
Nutr Cancer. 2020;72(5):778-790
pubmed: 31418286
Food Saf (Tokyo). 2016 Mar 30;4(1):14-27
pubmed: 32231900
Lancet. 2008 Jan 26;371(9609):340-57
pubmed: 18206223
Curr Dev Nutr. 2022 Jan 07;6(2):nzab153
pubmed: 35155983
Nature. 2020 Jan;577(7789):231-234
pubmed: 31915393
Mol Nutr Food Res. 2015 Mar;59(3):574-81
pubmed: 24668606
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2020 Dec;37(12):2123-2134
pubmed: 33026957
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2022 Aug;39(8):1463-1473
pubmed: 35652855
Curr Dev Nutr. 2023 Jun 10;7(7):101962
pubmed: 37426291
Crit Rev Food Sci Nutr. 2017 Jun 13;57(9):1963-1975
pubmed: 26176888
Int J Epidemiol. 2003 Aug;32(4):556-62
pubmed: 12913029
Toxins (Basel). 2022 Apr 19;14(5):
pubmed: 35622537
Int J Epidemiol. 2007 Oct;36(5):1119-25
pubmed: 17576701

Auteurs

Behnam Ghorbani Nejad (BG)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Zahra Mostafaei (Z)

Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Ali Balouchi Rezaabad (AB)

Department of Pharmacognosy, School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Fatemeh Mehravar (F)

Department of Psychiatry and Community Health Nursing School of Nursing and Midwifery, Golestan University of Medical Sciences (GOUMS), Golestan, Iran.

Mahtab Zarei (M)

Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.

Azadeh Dehghani (A)

Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Amin Raeisi Estabragh (MAR)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Somayyeh Karami-Mohajeri (S)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. s_karami@kmu.ac.ir.

Hamzeh Alizadeh (H)

Genetics Research Center, Department of Genetics and Breeding, The University of Guilan, Rasht, Iran. hamaliguilan@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH